Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
24 Sep 2024
Historique:
accepted: 19 08 2024
received: 14 02 2024
revised: 06 08 2024
medline: 24 9 2024
pubmed: 24 9 2024
entrez: 24 9 2024
Statut: aheadofprint

Résumé

Oncogenes can be activated in cis through multiple mechanisms including enhancer hijacking events and noncoding mutations that create enhancers or promoters de novo. These paradigms have helped parse somatic variation of noncoding cancer genomes, thereby providing a rationale to identify noncanonical mechanisms of gene activation. Here we describe a novel mechanism of oncogene activation whereby focal copy number loss of an intronic element within the FTO gene leads to aberrant expression of IRX3, an oncogene in T cell acute lymphoblastic leukemia (T-ALL). Loss of this CTCF bound element downstream to IRX3 (+224 kb) leads to enhancer hijack of an upstream developmentally active super-enhancer of the CRNDE long noncoding RNA (-644 kb). Unexpectedly, the CRNDE super-enhancer interacts with the IRX3 promoter with no transcriptional output until it is untethered from the FTO intronic site. We propose that 'promoter tethering' of oncogenes to inert regions of the genome is a previously unappreciated biological mechanism preventing tumorigenesis.

Identifiants

pubmed: 39316719
pii: 517961
doi: 10.1182/blood.2024024300
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Sunniyat Rahman (S)

University College London, London, United Kingdom.

Gianna Bloye (G)

University College London, London, United Kingdom.

Nadine Farah (N)

University College London, London, United Kingdom.

Jonas Demeulemeester (J)

VIB - KU Leuven, Leuven, Belgium.

Joana R Costa (JR)

University College London, London, United Kingdom.

David O'Connor (D)

University College London, London, United Kingdom.

Rachael Pocock (R)

University College London, London, United Kingdom.

Tanya Rapoz-D'Silva (T)

University College London, London, United Kingdom.

Adam Turna (A)

Lister Hospital, Stevenage, United Kingdom.

Soo Wah Lee (SW)

University College London, London, United Kingdom.

Adele K Fielding (AK)

UCL Cancer Institute, London, United Kingdom.

Juliette Roels (J)

Genentech, South San Francisco, California, United States.

Roman Jaksik (R)

Silesian University of Technology, Gliwice, Poland.

Małgorzata Dawidowska (M)

Institute of Human Genetics Polish Academy of Sciences, Poznan, Poland.

Pieter Van Vlierberghe (P)

Ghent University, Ghent, Belgium.

Suzana Hadjur (S)

University College London, London, United Kingdom.

Jim R Hughes (JR)

Oxford University, Oxford, United Kingdom.

James Davies (J)

University of Oxford, Oxford, United Kingdom.

Alejandro Gutierrez (A)

St. Jude Children's Research Hospital, Memphis, Tennessee, United States.

Michelle Kelliher (M)

UMass Chan Medical School, Worcester, Massachusetts, United States.

Peter Van Loo (P)

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Mark A Dawson (MA)

Peter MacCallum Cancer Centre, Melbourne, Australia.

Marc R Mansour (MR)

University College London, London, United Kingdom.

Classifications MeSH